Athira PharmaATHA
Market Cap: $20.8M
About: Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Employees: 67
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1.16% more ownership
Funds ownership: 56.74% [Q1] → 57.9% (+1.16%) [Q2]
1% less capital invested
Capital invested by funds: $59.6M [Q1] → $58.8M (-$770K) [Q2]
13% less funds holding
Funds holding: 75 [Q1] → 65 (-10) [Q2]
35% less call options, than puts
Call options by funds: $200K | Put options by funds: $308K
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Rodman & Renshaw Elemer Piros 43% 1-year accuracy 3 / 7 met price target | 3,964%upside $22 | Buy Initiated | 19 Aug 2024 |
JMP Securities Jason Butler 55% 1-year accuracy 23 / 42 met price target | 3,409%upside $19 | Market Outperform Reiterated | 20 Jun 2024 |
Financial journalist opinion
Based on 5 articles about ATHA published over the past 30 days